(Total Views: 644)
Posted On: 02/18/2021 7:57:52 PM
Post# of 153933
I disagree.
There are countless disease states with multiple billion dollar drugs competing with each other. In these multi-billion markets there isn't usually one drug prescribed and never anything else just because that one drug is "better". Plus there are many influences on what gets prescribed that go beyond how good and safe a drug is. Formularies, rebates, lobbyists, marketing, etc. We stand to take a lot of market share from some big companies but they won't fold because of Leronlimab. The FDA has a lot of issues but approving a drug that ticks all of their boxes is not one of them.
There are countless disease states with multiple billion dollar drugs competing with each other. In these multi-billion markets there isn't usually one drug prescribed and never anything else just because that one drug is "better". Plus there are many influences on what gets prescribed that go beyond how good and safe a drug is. Formularies, rebates, lobbyists, marketing, etc. We stand to take a lot of market share from some big companies but they won't fold because of Leronlimab. The FDA has a lot of issues but approving a drug that ticks all of their boxes is not one of them.
(6)
(0)
